Nitric Oxide-Based Medicine

We are leveraging our proprietary NITRICIL™ technology platform to develop innovative, first-in-class therapies for unmet medical needs across multiple therapeutic areas.

Our Pipeline

Product Candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approval

Program Highlight

Dermatology

SB206

Molluscum

Target reporting topline results before the end of Q2 2021

Infectious Disease

SB019

Coronavirus

First demonstration of antiviral effect of NO against SARS-CoV-2 in in vitro human airway Infection Model

Companion Animal

NVN4100 (New Chemical Entity)

Antimicrobial

Seeking potential strategic partner following PoC

Our People

Spotlight on:

Tomoko-Maeda-Chubachi, VP, Medical Dermatology

“Our collective work ethic and integrity are what drive our one common goal: the opportunity to provide innovative, effective and accessible therapy for patients.”

More About Our People

Our People

Spotlight On:

Andrew Novak, VP, Accounting & Business Operations

“Novan is comprised of a team that is driven by the desire to provide therapies in areas of significant unmet need. There is no shortage of innovative collaboration, and it is inspiring to share the same passion for developing solutions for patients and their families.”

More About Our People

Our People

Spotlight on:

Tammy Payne, Senior Director, Analytical Method Development

“The encouragement for collaboration throughout the entire Novan team is contagious. We embrace investing full devotion towards developing therapies through our novel and innovative technology.”

More About Our People

I Am Novan

Spotlight On:

The Novan Team

Novan is committed to using the power of the human body to create safe and effective treatments. We complement our internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions.

More About Our People